‘Global Overactive Bladder Treatment Market Set To Grow To $4.0bn By 2023’ says latest research by Visiongain

27 July 2018
Pharma

Visiongain’ has launched a new pharma report Global Overactive Bladder Treatment Market 2018-2028: Prescription Drugs, OTC Drugs, Short-term Therapy, Long-term Therapy
It is estimated that about one in six adults in the US and Europe have over active bladder syndrome. The prevalence rate of over active bladder increases with age and thus it is expected that over active bladder will become more common in the future as the average age of people living in the developed countries is significantly increasing. The Global Overactive bladder therapeutic market is growing rapidly, with large opportunity to grow in the untapped APAC region mainly because of the introduction of low-cost generic products in rapidly developing countries such as India and China.
The lead analyst of the report commented “The global overactive bladder therapeutic market is driven by several factors such as increasing prevalence of urinary incontinence, increasing awareness of the disease and its comorbidities, growing diagnosis and treatment rates as well as limited number of current players. Moreover, there are various national and international level policies being adopted by a growing number of countries to combat overactive bladder related symptoms”

Leading companies featured in the report include Allergan, Apotex, Astellas, Medtronic, Mylan, Pfizer, Sanofi.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read